A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Study Classification

INTERVENTIONAL

Study Start Date

2000-11-30

Study Completion Date

2001-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

HIV infection is a major global health problem. Survival and quality of life for HIV subjects has tremendously improved with the advent of a class of antivirals called protease inhibitors and the utilization of highly active combination therapy. However, such therapy has been associated with a syndrome called lipodystrophy. This lipodystrophy syndrome causes body shape changes; typically thinning and loss of fat from the arms, legs and face, with increased fat appearing in the abdomen and neck. There are also metabolic changes which occur, and subjects can develop increased triglycerides, increased cholesterol and an increased risk for diabetes as indicated by increasing insulin resistance. This study will take HIV positive subjects who have not yet started antiviral medications (treatment naive)and randomly assign them to one of two treatment arms. These treatment arms will be: Sustiva/Zerit/Epivir vs. Viracept/Zerit/Epivir The subjects will be treated and followed for two years and have extensive metabolic testing, skinfold thickness measurements, MRI scans and other measures to determine if and how they are experiencing changes in metabolism or body shape and to discover the mechanism of why this occurs. Understanding the mechanism should allow researchers to design interventions for subjects who have lipodystrophy and strategies to prevent lipodystrophy from occurring to subjects treated with antivirals in the future.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Mechanisms of Lipodystrophy in HIV-Infected Pateints

NCT00457665

HIV Infections

COMPLETED PHASE4

Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome

NCT00006185

HIV Infections Lipodystrophy Insulin Resistance

COMPLETED PHASE1

Metabolism and Body Shape of Healthy Children and Children With Chronic Infections

NCT00001142

HIV Infections Healthy Hyperlipidemia +1 more

COMPLETED

Observational Study of Fat Loss in HIV Infected Adults Taking Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

NCT00119405

HIV Infections Lipodystrophy Metabolic Diseases +1 more

COMPLETED

Prevalence of Lipodystrophy Syndrome and Its Role as Cause of Metabolic Disturbances

NCT02614027

Lipodystrophy Metabolic Syndrome

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections Lipodystrophy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nelfinavir mesylate

Intervention Type DRUG

Stavudine

Intervention Type DRUG

Lamivudine

Intervention Type DRUG

Efavirenz

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* CD4 count \> 200 cells/mm
* HIV RNA (viral load) \<= 100,000 copies/ml
* No previous antiviral therapy

Exclusion Criteria

* AIDS or opportunistic infections
* Active intravenous drug users
* Use of: corticosteroids, androgens, lipid-lowering drugs, anti-fungal medications, oxandrolone, megace, dehydroepiandrosterone.
* Subjects with diabetes mellitus
* Subjects who consume \> 2 alcoholic drinks per day
* Pregnant women, premenopausal women unless adequate birth control is in use.
* Acute or chronic liver diseases, liver enzymes elevations \> 2.5 times the upper limit of normal.
* Anemia, an Hct \< 35% for men, or \< 32% for women.
* Abnormal thyroid function tests.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No